Last Update 11 Apr 26
I was very pessimistic about RXRX! I am now extremely optimistic and here’s why! The former CEO has finally stepped down and now Najat Khan who is extremely smart takes over for a company that was heading south. With her leadership shexwilk being RXRX back to respectability and accountability as well! CMO has also transitioned out. Viki Goodman MD is a seasoned veteran with an excellent track record! RXRX should be heading north in price very soon! Don’t forget the former CEO and CMO had 3 advanced drug trials that failed! These comments according to many investors in the know! I believe RXRX will one day be the Palantir of biotechnology!!!!
RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said
Have other thoughts on Recursion Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user 537578 holds no position in NasdaqGS:RXRX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
